Reducing Risk Of Alzheimer's Disease

Scientists have developed a blood-based test that could be used to predict the risk of Alzheimer's disease up to 3.5 years before clinical diagnosis. The research, published in the journal Brain, supports the idea that components in the human blood can modulate the formation of new brain cells, a process termed neurogenesis. Neurogenesis occurs in an important part of the brain called the hippocampus that is involved in learning and memory. While Alzheimer's disease affects the formation of new brain cells in the hippocampus during the early stages of the disease, previous studies have only been able to study neurogenesis in its later stages through autopsies. To understand the early changes, researchers collected blood samples over several years from 56 individuals with Mild Cognitive Impairment (MCI), a condition where someone will begin to experience a worsening of their memory or cognitive ability. While not everyone experiencing MCI goes on to develop Alzheimer's disease, tho

A new drug, lecanemab, has been found to slow down cognitive decline in Alzheimer's patients, according to a study that could lead to new treatments for the neurodegenerative disease. The study results were presented at the 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference in San Francisco, US, on November 29. The study is also published in the New England Journal of Medicine. Amyloid-clearing and cognitive decline-slowing drug lecanemab, which is poised for FDA approval early next year, will be a positive step in the treatment of Alzheimer's, the study said. Alzheimer's is a complex disease with multiple underlying causes tied to the biology of aging, therefore, the Alzheimer's Drug Discovery Foundation (ADDF) has long held that a combination drug approach is needed, the study said. Alzheimer's Drug Discovery Foundation (ADDF) is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer's disease. "Today's results show that lecanema

Alzheimer's Day 2021: A hallmark of Alzheimer's disease is gradual deterioration of memory. Here's all you need to know about the disease on World Alzheimer's Day 2021

World Alzheimer's Day 2021: Typically, Alzheimer's disease is associated with degeneration of brain cells (neurons) and related dementia that affects memory.

Alzheimer's disease is a type of dementia; in fact it is the most common type of dementia. Around 70% cases of dementia are that of Alzheimer's disease.